Inactive Instrument

Company Atossa Genetics Inc Nasdaq

Equities

US04962H2094

Biotechnology & Medical Research

Business Summary

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).

Managers

Managers TitleAgeSince
Founder 62 08-11-30
Chief Executive Officer 73 08-11-30
Director of Finance/CFO - 16-12-31
Chief Tech/Sci/R&D Officer - Dec. 03
Chief Tech/Sci/R&D Officer - 22-10-24
Chief Administrative Officer - 13-12-31
Investor Relations Contact - 22-12-06

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 73 08-11-30
Director/Board Member 66 14-02-28
Director/Board Member 72 12-01-31
Founder 62 08-11-30
Director/Board Member 77 11-06-30
Director/Board Member 50 Nov. 07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 126,624,110 125,230,652 ( 98.90 %) 1,320,046 ( 1.042 %) 98.90 %
Stock B 0 582 0 0

Shareholders

NameEquities%Valuation
Vanguard Global Advisers LLC
4.592 %
5,753,993 4.592 % 9 M $
BlackRock Advisors LLC
2.091 %
2,619,487 2.091 % 4 M $
Laurion Capital Management LP
1.776 %
2,225,800 1.776 % 3 M $
Renaissance Technologies LLC
1.106 %
1,386,370 1.106 % 2 M $
Geode Capital Management LLC
0.9675 %
1,212,323 0.9675 % 2 M $
436,271 0.3482 % 663 132 $
HRT Financial LLC
0.2326 %
291,421 0.2326 % 442 960 $
Susquehanna Securities LLC
0.2172 %
272,115 0.2172 % 413 615 $
Gescooperativo SA SGIIC
0.1996 %
250,169 0.1996 % 380 257 $
Qube Research & Technologies Ltd. (France)
0.1985 %
248,708 0.1985 % 378 036 $
NameEquities%Valuation
Ensisheim Partners LLC
1.192 %
8 1.192 % 12 $
Kyle Guse
1.192 %
8 1.192 % 12 $

Company contact information

Atossa Therapeutics, Inc.

107 Spring Street

98104, Seattle

+206 588 0256

http://www.atossatherapeutics.com
address Atossa Genetics Inc
  1. Stock Market
  2. Equities
  3. ATOS Stock
  4. Stock
  5. Company Atossa Genetics Inc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW